Plain-English translation of NCT05949931 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called Penpulimab combined with a standard chemotherapy regimen (AVD) to treat newly diagnosed advanced Hodgkin lymphoma, a type of cancer affecting the lymph nodes. Researchers want to see whether adding this new immune-boosting medication to the standard treatment improves outcomes and is safe for patients. The study will compare two different schedules: giving the medication at the same time as chemotherapy, or giving it before and after chemotherapy.
Advanced Hodgkin lymphoma is a serious condition, and while standard chemotherapy works for many patients, doctors are looking for ways to improve results. This medication is designed to boost the immune system's ability to fight cancer, and researchers believe combining it with standard treatment might help more patients achieve long-term remission.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive treatment in cycles over several months. Depending on which study group you're assigned to, you'll either receive the new medication and chemotherapy together for 6 cycles, or you'll receive the new medication first for 3 cycles, followed by chemotherapy alone for 6 cycles, then the new medication again for 3 cycles. Each cycle lasts 28 days, and you'll receive injections on day 1 and day 15 of each cycle. You'll have regular appointments at the hospital for treatment and monitoring, with blood tests and scans to track how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sun Yat-sen University
Enrollment target
~108 participants
Started
October 2023
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qingqing Cai, MD. PhD.
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.